This announcement is a separate document:
南京医药：南京医药监事会关于公司2021年限制性股票激励计划预留授予部分第一个解除限售期解除限售名单的核查意见
Nanjing Pharmaceutical: Nanjing Pharmaceutical Supervisory Board\'s inspection opinion on the Company\'s 2021 Restricted Stock Incentive Plan reserves and grants part of the first sales restriction period to lift the sales restriction list
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.